Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) (FRA:6ZY) is a pharmaceutical company focused on developing and marketing synthetic cannabinoid therapeutics for transdermal delivery. These therapetics seek to meet the unmet needs of patients with epilepsy, osteoarthritis, fibromyalgia, peripheral neuropathic pain, and Fragile X syndrome. Zynerba’s product pipeline includes two drugs being developed: ZYN001 and ZYN002. ZYN001 is a THC Pro-Drug Patch providing transdermal THC delivery for fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic CBD gel providing transdermal non-psychoactive CBD delivery for epilepsy, osteoarthritis, as well as Fragile X syndrome.